1971 to 2017 Saw 32 Drinking Water Hepatitis A Outbreaks
Thirty-two outbreaks of hepatitis A associated with drinking water were identified during 1971 to 2017, and all occurred before 2010.
Liver
LIVER
Latest Articles
Mycophenolate Mofetil Does Not Top Methotrexate in Noninfectious Uveitis
For adults with noninfectious uveitis, mycophenolate mofetil is not associated with superior control of inflammation compared with methotrexate.
Common Therapy for Obstetric Cholestasis Found Ineffective
For women with intrahepatic cholestasis of pregnancy, treatment with ursodeoxycholic acid does not reduce adverse perinatal outcomes, according to a study published online Aug. 1 in The Lancet.
FDA: Cases of Serious Liver Injury Reported With Certain HCV Agents
The FDA is warning healthcare professionals that cases of liver decompensation, including liver failure and death, have been linked to certain hepatitis C drugs.
Aspirin May Improve Liver Function After Embolization of HCC
Aspirin therapy can improve liver function and survival in patients who have received chemoembolization or transarterial embolization for hepatocellular carcinoma.
Fluoride Exposure Tied to Kidney, Liver Function Changes in Youth
This study’s findings suggest that there may be potential kidney and liver health concerns to consider when evaluating fluoride use and appropriate levels in public health interventions.
DAA Therapy Benefits Patients With HCV and HCC
Direct-acting antiviral therapy may be a beneficial therapy for patients infected with HCV with a history of hepatocellular carcinoma by increasing overall survival.
Patients With Porphyria Cutanea Tarda Have Higher Mortality Risk
Patients with porphyria cutanea tarda have increased all-cause mortality and risk for death because of gastrointestinal diseases and cancer of the gut, liver, gallbladder, and lungs.
FDA Reports Rare Cases of Liver Injury, Failure With Hep C Therapies
FDA reports rare cases of worsening liver function or liver failure in patients with chronic hepatitis C virus (HCV) who had moderate-to-severe liver impairment and were treated with Mavyret, Zepatier, or Vosevi, despite these drugs being contraindicated in this group of patients.
Kynurenine:Tryptophan Ratio Linked to Liver Fibrosis in Women With HIV, HCV
In people with HIV, the kynurenine/tryptophan (kyn/trp) ratio is elevated and is associated with greater liver fibrosis.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to peginterferon lambda (Lambda; Eiger BioPharmaceuticals) for the treatment of hepatitis delta virus (HDV) infection.
The FDA has granted Breakthrough Therapy designation to peginterferon lambda (Lambda; Eiger BioPharmaceuticals) for the treatment of hepatitis delta virus (HDV) infection.
USPSTF Advises Broader Age Range for Hep C Screening
Draft recommendation statement expands screening to asymptomatic individuals aged 18 to 79 years
DAAs Cut Deaths in Those Treated for HCV-Related Liver Cancer
Among patients with hepatitis C virus (HCV) infection and complete response to hepatocellular carcinoma (HCC) treatment, direct-acting antiviral (DAA) therapy is associated with a significant reduction in the risk for death.
Evaluating Long-Term Outcomes of Pediatric-Onset Primary Sclerosing Cholangitis
Researchers conducted a retrospective cohort study to determine the clinical features of pediatric patients with PSC in a Japanese cohort to evaluate long-term outcomes. They discovered that primary sclerosing cholangitis (PSC)-autoimmune hepatitis overlap is the primary phenotype linked to poor long-term outcomes.
High Efficacy of Resistance-Guided Retreatment of Patients With Hepatitis C Virus
In Spain, researchers found data from a real-world cohort that showed that retreatment and a sustained viral response, depending upon treatment nonresponse and genotype, can be achieved with certain combinations of direct-acting antivirals.
Lipophilic Statins May Cut Liver Cancer in Chronic Viral Hepatitis
The researchers found that lipophilic statin users had a significantly lower 10-year HCC risk compared with matched nonusers (8.1 versus 3.3 percent; absolute risk difference [RD], −4.8 percent; adjusted subdistribution hazard ratio [aHR], 0.56; 95 percent confidence interval [CI], 0.41 to 0.79), while hydrophilic statin users did not have a lower risk (8.0 versus 6.8 percent; RD, −1.2 percent; aHR, 0.95; 95 percent CI, 0.86 to 1.08).
Liver Stiffness Measurement as a Potential Screening Tool for Liver-Related Events in HCV
Measuring liver stiffness may be a feasible community screening tool to predict liver-related adverse events.
Hospital vs Primary Care Comparison of Treatment Outcomes in Hepatitis C
Researchers in Australia found that treatment with direct acting antivirals for hepatitis C in the primary care setting is effective in treatment uptake in people who inject drugs, compared with referrals to hospital-based services.
HCV, HIV Association With Peripheral Artery Disease Examined
Investigators analyzed the relationship between HIV, hepatitis C virus, and peripheral artery disease in women.
Diabetes and Hepatitis C: A Need for Integrated Pharmacologic Management
Researchers found data that showed hepatitis C virus infection is linked to an increased risk for diabetes mellitus in both chronic hepatitis patients and patients with cirrhosis from hepatitis C.
Want to read more?
Please login or register first to view this content.
Next post in Liver
